Cognition Therapeutics presents preclinical data on sigma-2 modulators

Cognition Therapeutics is presenting in vivo preclinical results at the Society for Neuroscience’s annual meeting illuminating the role of sigma-2 receptor modulators, including CT1812, in models of Alzheimer’s and Parkinson’s diseases. The effect of two chemically distinct -2 receptor modulators in a mouse model of Alzheimer’s disease on gene and protein expression are presented. Data shed light on the molecular mechanisms and build upon previous studies in this same mouse model where Cognition’s lead candidate, CT1812 was previously shown to decrease binding of Abeta oligomers to neuronal synapses and ameliorate cognitive deficits. Mary Hamby, Ph.D., Cognition’s VP of research, explained, “These findings help to broaden our understanding of the role of the -2 receptor in central nervous system diseases, and support continued discovery and development of candidates that modulate this therapeutic target for Alzheimer’s disease, dementia with Lewy bodies, and Parkinson’s disease.”